Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Anlotinib with Chemotherapy in Malignant Pleural Mesothelioma
NCT05188859Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab and anlotinib in malignant pleural mesothelioma (MPM), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Sep 2024; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05188859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188859.